22.4 C
Los Angeles
September 22, 2023

Pharma Company Announces 64% YoY Dip In PAT, Rs 30/Share Dividend

Pharma Company Announces 64% YoY Dip In PAT, Rs 30/Share Dividend


oi-Renu Baliyan


Large cap company operating in Pharmaceuticals sector, Divi’s Laboratories Ltd on Saturday reported 64% YoY decline in consolidated net profit for the March quarter to Rs 321 crore. Board of directors of Divi’s Laboratories recommended a dividend of Rs 30/- per equity share (i.e. 1500%) for FY 2022-23. Check details below:

Divi’s Laboratories Declares Dividend: According to the BSE filing of the company, “Recommended a Dividend of ₹ 30/- (i.e. 1,500%) per equity share of face value Rs 2/- each for the financial year 2022-23, subject to approval of the members at the ensuing 33rd Annual General Meeting (AGM). The dividend shall be credited / warrants thereof dispatched within specified timelines from the conclusion of the AGM. The AGM date and record date for the purpose of the payment of dividend will be announced in due course.”

Pharma Company Announces 64% YoY Dip In PAT, Rs 30/Share Dividend

Divi’s Laboratories Stock Performance & Return: The last trading price of Divi’s Laboratories is Rs 3097.75 per share with intraday fall of 1.86%. The stock’s 52-week high price is Rs 4438.30 apiece and 52-week low price is Rs 2730.00 apiece, respectively. The company’s market capitalisation is Rs 82,235.53 crore. The stock surged 9% in last 3-months, declined 26% in last 1-year, 23% in last 2-years, and gave return of 33% in last 3-years. The shares of Divi’s Laboratories soared 168% in last 5-years.

Divi’s Laboratories Q4: The company’s consolidated revenue too witnessed a dip of 22.5% YoY to Rs 1951 crore. Sequentially, Divi’s Laboratories’ net profit surged approximately 5% in the March quarter and revenue soared by 14.2%.

Meanwhile, operating profit, calculated as earnings before interest, taxes, depreciation and amortization (EBITDA), witnessed a dip of 56% YoY to Rs 488 crore for Q4, and operating margin dipped 1886 basis points to 24.99%.

It declared a 38.4% decline in net profit for FY23 to Rs 1,823 crore and revenue plunged by more than 13% to Rs 7,768 crore.

About Divi’s Laboratories: Established in the year 1990, Divi’s is a leading manufacturer of Active Pharmaceutical Ingredients offering high quality products to over 95 countries, according to its official website.

Story first published: Saturday, May 20, 2023, 13:56 [IST]

Related posts

2022 US Wealth Management Outlook: All Aboard the Crypto Train?


Ionic Leach Trial Successfully Detects Mineralisation 500m Below Surface At Sams Creek


Reliance’s Operating Performance To Remain Resilient: S&P


Leave a Comment

Translate »